Luca Cantini
Università Politecnica delle Marche
H-index: 19
Europe-Italy
Top articles of Luca Cantini
85P NSCLC-Pro ClustAI: A machine learning model to prognostically stratify patients with advanced NSCLC treated with immune checkpoint inhibitors
ESMO Open
2024/3/1
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research
Clinical Lung Cancer
2024/3/1
Prognostic impact of blood lipid profile in patients with advanced solid tumors treated with immune checkpoint inhibitors: a multicenter cohort study
The Oncologist
2024/3/1
SARS-CoV-2 omicron (B. 1.1. 529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry
The Lancet Oncology
2023/4/1
Alessio Cortellini
H-Index: 17
Bruno Vincenzi
H-Index: 42
Giuseppe Tonini
H-Index: 48
Francesco Pantano
H-Index: 22
Paolo Pedrazzoli
H-Index: 10
Cian Murphy
H-Index: 10
Lee Cooper
H-Index: 29
Sarah Ahmed
H-Index: 1
Francesca Mazzoni
H-Index: 12
Alessandro Parisi
H-Index: 6
Meera Patel
H-Index: 7
Beth Russell
H-Index: 3
Sven Mahner
H-Index: 43
Lorenza Scotti
H-Index: 32
Marco Filetti
H-Index: 14
Rossana Berardi
H-Index: 37
Luca Cantini
H-Index: 6
Marco Tagliamento
H-Index: 11
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
2023/12/10
Luca Cantini
H-Index: 6
1065P Prospective assessment of nutritional status in patients with advanced non-small cell lung cancer and renal cell carcinoma treated with immune checkpoint inhibitors
Annals of Oncology
2023/10/1
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study
JNCI: Journal of the National Cancer Institute
2023/7/1
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors
Cancer Immunology, Immunotherapy
2023/7
66P Outcome predictors for pembrolizumab alone or with chemotherapy in advanced non-small cell lung cancer (NSCLC)
Journal of Thoracic Oncology
2023/4/1
COVID-19 sequelae and the host proinflammatory response: an analysis from the OnCovid registry
JNCI: Journal of the National Cancer Institute
2022/7/1
Extended interval dosing in patients with cancer receiving immune checkpoint inhibitors: Safety analysis from the EDICI study.
2022/6/1
Pachychoroid spectrum disease and choriocapillary flow analysis in patients with Cushing disease: An optical coherence tomography angiography study
Graefe's Archive for Clinical and Experimental Ophthalmology
2022/5
Luca Cantini
H-Index: 6
91 Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors
2022/11/1
164P Immune modulatory functions of lurbinectedin in small cell lung cancer and malignant pleural mesothelioma patients
Annals of Oncology
2022/4/1
Rising incidence of late stage breast cancer after COVID-19 outbreak. Real-world data from the Italian COVID-DELAY study
The Breast
2022/10/1
Luca Cantini
H-Index: 6
Rossana Berardi
H-Index: 37
Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a …
ESMO open
2022/4/1
The landscape of ALK-rearranged non-small cell lung cancer: A comprehensive review of clinicopathologic, genomic characteristics, and therapeutic perspectives
2022/9/29
Luca Cantini
H-Index: 6
Rossana Berardi
H-Index: 37
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world …
ESMO open
2022/4/1
1642TiP ENSURE: Dendritic cell therapy (MesoPher) in combination with extended-pleurectomy/decortication after chemotherapy in subjects with resectable mesothelioma: A …
Annals of Oncology
2022/9/1
Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition
2022/3/1
Luca Cantini
H-Index: 6
Daniel Sterman
H-Index: 34
